

Changes in cardiorespiratory function and fatigue following 12 weeks of exercise training in women with systemic lupus erythematosus: a pilot study

Sarfraz Hasni ,¹ Li Rebekah Feng,² Marquis Chapman,¹ Sarthak Gupta,³ Anam Ahmad,⁴ Adam Munday,¹ Mir Ali Mazhar,¹ Xiaobai Li,⁵ Shajia Lu,⁶ Wanxia Li Tsai,⁶ Massimo Gadina,⁶ Michael Davis,¹ Jun Chu,¹ Zerai Manna,¹ Shuichiro Nakabo,³ Mariana J Kaplan ,³ Leorey Saligan,⁷ Randall Keyser,⁴ Leighton Chan,⁴ Lisa M K Chin⁴

To cite: Hasni S, Feng LR, Chapman M, *et al.* Changes in cardiorespiratory function and fatigue following 12 weeks of exercise training in women with systemic lupus erythematosus: a pilot study. *Lupus Science & Medicine* 2022;**9**:e000778. doi:10.1136/lupus-2022-000778

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/lupus-2022-000778>).

Received 13 July 2022
Accepted 23 September 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Sarfraz Hasni; sarfraz.hasni@nih.gov

ABSTRACT

Objective In patients with systemic lupus erythematosus (SLE), fatigue is a debilitating symptom with poorly understood pathophysiology. Cardiorespiratory dysfunction has been hypothesised as a contributor to SLE-fatigue. The purpose of this exploratory study was to examine changes in cardiorespiratory function, following an exercise training programme in women with SLE, together with patient reported outcomes and other pathophysiological measures that may underlie SLE-fatigue.

Methods Sixteen women with SLE and fatigue (Fatigue Severity Scale (FSS) ≥ 3) were enrolled in a supervised aerobic exercise training programme of vigorous intensity. The primary outcome was time to reach anaerobic threshold (AT-Time) during a cardiopulmonary exercise test (CPET). Secondary outcomes included changes in the 10-minute walk test (10MWT), FSS scores and the Patient Reported Outcomes Measurement Information System (PROMIS-57) survey. Mitochondrial function was assessed by the oxygen consumption rate (OCR)/extracellular acidification rate (ECAR) metabolic potential ratio.

Results Following 12 weeks of exercise training, AT-Time increased by 93 ± 82 (mean \pm SD) s ($p < 0.001$), 10MWT increased by 84 ± 66 m ($p < 0.001$) and peak oxygen uptake (VO_2) increased by 1.4 ± 2.0 mL/kg/min ($p = 0.013$). There were improvements in FSS score (-1.4 ± 1.0 , $p < 0.0001$) and in most of the PROMIS-57 domains. The decrease in FSS scores correlated with an increase in the OCR/ECAR ratio (Pearson's correlation $r = -0.59$, $p = 0.03$). A subset of subjects (9/15) had significant reduction in their Interferon Stimulated Genes (ISG) ($p = 0.007$) accompanied by a significant increase in the OCR/ECAR ratio ($p = 0.013$).

Conclusions Cardiorespiratory function was improved in concomitance with reductions in fatigue following a 12-week aerobic exercise programme. The reduction in fatigue scores correlated with improvements in mitochondrial function.

INTRODUCTION

One of the most debilitating symptoms of systemic lupus erythematosus (SLE) is excessive fatigue (SLE-fatigue), which persists even during periods of negligible disease activity or remission, is associated with physical activity intolerance and poor cardiopulmonary fitness.¹ Cardiorespiratory dysfunction associated with fatigue may result from underlying pathophysiological processes and physiological deconditioning, other possible contributing factors include left ventricular dysfunction, pulmonary hypertension, interstitial lung disease and muscle atrophy.²

Aberrant mitochondrial function is shown to be associated with SLE-fatigue which improved on reversal of mitochondrial oxidative stress by repletion of glutathione by administration of N-acetylcysteine.³ Mitochondrial dysfunction also led to dysregulation in the type I interferon (IFN) pathway thereby promoting immune dysregulation, suggesting a putative role in SLE-fatigue.^{4,5} These studies suggest a putative role of mitochondrial dysfunction in SLE-fatigue.

The purpose of this exploratory study was to examine changes in objective measures of cardiorespiratory function and patient reported outcomes following an exercise training programme in women with SLE, and explore its association with measures of mitochondrial function. The primary outcome was time to attain the anaerobic threshold (AT-Time) during the cardiopulmonary exercise test (CPET). Secondary outcome measures were peak exercise capacity during the CPET and 10-minute walk test (10MWT).

METHODS

Study design

The study was approved by the National Institutes of Health (NIH) Institutional Review Board (ClinicalTrials.gov NCT03186794). Eligible subjects performed CPET and 10MWT, completed the Fatigue Severity Scale (FSS) and Patient Reported Outcomes Measurement Information System (PROMIS-57) survey, participated in exercise training and repeated all the assessments at the end.

Subjects

Eligible subjects met the American College of Rheumatology (ACR) Revised Criteria for the Classification of SLE and had a Safety of Estrogen in Lupus Erythematosus, National Assessment modification of Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score of ≤ 4 and FSS score ≥ 3 . Sixteen subjects completed the study (online supplemental figure 1).

Study procedures

Cardiopulmonary exercise test (CPET)

All subjects walked on a treadmill to an individualised increase in work rate projected to reach 8 METS in 10 min, with cardiorespiratory monitoring throughout the CPET (CardiO2 Ultima; MedGraphics Corp, St. Paul, Minnesota, USA). The target endpoint was volitional exhaustion by the subject. Anaerobic threshold (AT) was verified using accepted gas exchange analysis methods and peak oxygen consumption (peakVO_2) was an average of the final 20 s of the CPET.² Respiratory exchange ratio (RER) was calculated as the ratio of CO_2 production to O_2 consumption (VCO_2/VO_2).

Exercise training sessions

Supervised aerobic exercise training sessions comprised of treadmill walking, three times a week, over a period of 12 weeks, attending at least 29 out of 36 sessions. The goal was to complete 30 continuous minutes of vigorous intensity exercise (70%–80% of heart rate reserve).

10-Minute walk test (10MWT) and fatigability indices

A 10MWT was used to determine overground walking capacity by measuring the total distance walked in 10 minutes. Perceived and performance fatigability were measured using the methods of Schnelle and associates.⁶

Patient reported outcomes

The FSS evaluates the impact of fatigue on patients' physical and social functioning and the PROMIS-57 survey captures quality of life over eight domains.

Statistical analysis

Sample size was chosen based on feasibility and convenience, no formal determination were performed. Paired t-tests or Wilcoxon signed-rank test was used to determine if significant changes (post-training – pre-training) in the primary and secondary outcome measures were observed after the exercise training regimen. A Pearson's correlation was calculated to examine the association between

changes in FSS and OCR/ECAR ratio, baseline performance fatigability and change in performance fatigability at the end of study. A two-sided p value less than 0.05 was used to indicate statistically significant difference or relationship. Linear mixed effects models were used to analyse the longitudinal cytokines data, with visit as the fixed effect. An unstructured variance covariance matrix was used to account for the correlations among the repeated measures with the subject. For the comparisons of the cytokines between the pre-exercise visit and the post-exercise visit, the final p values were adjusted by the FDR (false discovery rate) method. Statistical analyses were performed in SAS (V.9.4, SAS Institute).

See online supplemental material for additional methods.

RESULTS

Patient characteristics

Sixteen subjects completed the study and were included in the analyses. Almost all the subjects belonged to racial/ethnic minority groups (table 1). Disease activity and damage accrual at enrolment were low and no flares or changes in damage were observed during the study (Appendix—online supplemental table 1). The average

Table 1 Baseline characteristics of subjects (n=16) completing the study

Age, years	42.0 \pm 10.3
Disease duration, years	9.1 \pm 6.5
BMI, kg/m ²	28.2 \pm 5.2
Race/ethnicity, n (%)	
White	2 (12.5%)
African-American	3 (18.8%)
Asian	3 (18.8%)
Hispanic	8 (50%)
Gender, n (%)	
Female	16 (100%)
SELENA-SLEDAI	1.4 \pm 1.9
SLICC/ACR DI	0.8 \pm 1.2
Drugs, n (%)	
Glucocorticoids	11 (68.7%)
Antimalarials	15 (93.7%)
Azathioprine	5 (31.2%)
Methotrexate	2 (12.5%)
Mycophenolate mofetil	6 (37.5%)

Values are means \pm SD or count and percentage of total sample, n=number of patients.

BMI, body mass index; SELENA-SLEDAI, Safety of Estrogen in Lupus Erythematosus, National Assessment modification of Systemic Lupus Erythematosus Disease Activity Index; SLICC/ACR DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.

Table 2 Results of the CPET, patient reported outcomes and 10MWT (n=16)

	Pre-training	Post-training	Δ (post-pre)	P value
CPET variables (mean±SD)				
Peak exercise measures				
Treadmill time (s)	837 (203)	916 (153)	+79 (86)	0.002*
VO ₂ (mL/kg/min)	21.7 (3.5)	23.1 (3.8)	+1.4 (2.0)	0.013*
WR (W)	174 (55)	195 (46)	+21 (24)	0.004*
HR (beats/min)	157 (17)	154 (16)	-2 (12)	0.443
RER	1.18 (0.11)	1.17 (0.11)	-0.01 (0.07)	0.445
Submaximal exercise measures (at the anaerobic threshold)				
Treadmill time (s)	341 (144)	435 (130)	+93 (82)	< 0.001**
VO ₂ (mL/kg/min)	12.1 (2.4)	13.3 (2.6)	+1.2 (1.1)	<0.001**
HR (beats/min)	108 (15)	106 (10)	-2 (8)	0.193
WR (W)	44 (35)	68 (30)	+24 (21)	< 0.001**
Patient reported outcomes (mean±SD)				
FSS average all domains combined	4.6±1.2	3.1±1.4	-1.4±1.0	<0.0001**
10MWT				
Distance (m)	925 (131)	1009 (121)	+84 (66)	<0.001**
Performance fatigability index	1.11 (0.17)	0.99 (0.12)	-0.12 (0.09)	<0.001**
Perceived fatigability index	4.88 (1.92)	4.45 (2.11)	-0.43 (1.55)	0.501

*p<0.05; **p<0.001. Paired two-tailed, t-test were used for all results, except peak HR, VO₂ for the AT, performance fatigability index and perceived fatigability index where a Wilcoxon signed-rank test was used. Shapiro-Wilk normality test was performed to evaluate normality assumption. No adjustments were made for multiple comparisons.

CPET, cardiopulmonary exercise test; FSS, Fatigue Severity Scale; HR, heart rate; 10MWT, 10-minute walk test; RER, respiratory exchange ratio; VO₂, oxygen consumption; WR, work rate.

prednisone dose was 5 mg and there were no changes made in medication regimens throughout the study.

Exercise capacity and fatigability

Subjects attended 92% of exercise training sessions (Appendix—online supplemental table 2) and spent 95% of their exercising time during these sessions at or above the target HR range. There were no serious adverse events associated with exercise training.

At baseline CPET, 15 out of 16 subjects attained a HR ≥90% of age-predicted maximum HR (220 bpm—age) or peak RER≥1.10 (15/16 subjects) (table 2 and Appendix—online supplemental figure 2). Significant improvement in the primary outcome of AT-Time (+93 s, p<0.001) was observed after exercise training, as well as other outcomes at peak exercise (table 2 and figure 1) indicating overall improved cardiorespiratory function.

The average post-exercise training distance covered by subjects during 10MWT increased by 84 m (p<0.001) (table 2). A significant improvement in performance fatigability index (-0.12, p<0.001) was noted post-exercise training (table 2). An inverse relationship between the baseline and change in performance fatigability scores was noted (r=-0.747, p=0.001), suggesting that those experiencing the highest degrees of fatigability improved the most

(online supplemental figure 3). The change in perceived fatigability index was not significant (-0.43, p=0.50).




Figure 1 Time to reach the anaerobic threshold (AT-Time) at pre-training and post-training. Data are shown for each subject (symbols and lines) (n=16), with pre-training (black) and post-training (grey) comparisons shown as group means±SD. After 12 weeks of aerobic exercise training, subjects took longer to achieve the AT demonstrating improved fatigability (p<0.001).

Patient reported outcomes

The composite FSS score was reduced after exercise training (-1.3 , $p < 0.0001$) (table 2). In addition, each of the individual FSS domains also significantly improved after exercise training (online supplemental table 3). There were significant improvements in most PROMIS-57 domains (Appendix—online supplemental table 4).^{3,7}

Mitochondrial responses

An inverse relationship between the post-training change in OCR/ECAR and FSS scores ($r = -0.59$, $p = 0.03$) was observed (online supplemental figure 4).

DISCUSSION

The current study demonstrated significant improvements in objective measures of cardiorespiratory function and patient-reported fatigue following a vigorous treadmill walking programme in patients with SLE. Exploratory data suggested an improvement in mitochondrial function with an inverse correlation between fatigue and mitochondrial function following exercise training. The exercise programme was well tolerated with no serious adverse effects.

Peak VO_2 (measured during a CPET) is accepted as gold standard measurements for cardiorespiratory function, while the anaerobic threshold (AT) is a marker of cardiorespiratory endurance. In the current study, there was an increase in peak VO_2 of 7% which was lower compared with previous studies, perhaps as subjects in this study were older with higher damage accrual.⁸ The current study resulted in an increase in AT-Time and CPET duration after exercise training, indicating an improvement in metabolic function and exercise tolerance. Subjects also had large gains in the 10MWT distance and performance fatigability (table 2), these improvements were greatest in subjects with the worst performance fatigability at baseline (online supplemental figure 3).

Consistent with previous studies, participants reported a significant improvement in fatigue and physical function.^{8–10} Select domains of PROMIS-57 did not change in this study (ie, anxiety, satisfaction with social roles and pain). Previous studies have also shown improvement in physical fatigue, physical role and vitality domains of 36-Item Short Form Survey (SF-36), but unlike our study, there was no improvement in domains of depression and sleep. Indeed, conflicting results for psychosocial and cognitive function outcomes are reported in the literature, suggesting additional regulators of SLE-fatigue such as psychological factors and pain, may need to be addressed.^{8,9,11}

Mitochondrial dysfunction has been reported in SLE and proposed as a putative biological mechanism for chronic fatigue.⁴ In the current study, we observed an inverse correlation between mitochondrial function and SLE-fatigue with exercise training, and a post-exercise improvement in mitochondrial dysfunction. These data

suggest mitochondrial dysfunction as perhaps one of the determinants and a therapeutic target for SLE-fatigue.¹⁰

Our study has limitations. We did not include control group of subjects with or without SLE. However, our main outcome variable was objective measure of adaptation to aerobic exercise training and less likely to be subjected to observational bias. Our study included a small number of subjects, all of whom were highly motivated, which is in contrast to a survey showing only 28% of patients with SLE engage in moderate-to-vigorous intensity physical activity.¹²

In summary, this single treatment-arm study of supervised exercise training demonstrated improvements in objective measures of exercise capacity and patient reported fatigue. Novel insights into mitochondrial dysfunction and their potential improvement after exercise training were also underscored. The study has emphasised associations among improvements in cardiorespiratory function, performance fatigability and SLE-fatigue, and provides further evidence that exercise training may be an effective adjunct to treatment in women with SLE.

Author affiliations

¹Lupus Clinical Trials Unit, Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA

²National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA

³Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA

⁴Rehabilitation Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA

⁵Biosstatistics and Clinical Epidemiology service, National Institutes of Health Clinical Center, Bethesda, MD, USA

⁶Translational Immunology Section, National Institute of Arthritis, and Musculoskeletal, and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA

⁷National Institutes of Health, Bethesda, Maryland, USA

Twitter Sarthak Gupta @SarthakGuptaMD

Acknowledgements The authors would like to acknowledge the following for their contribution to the study: Bart Drinkard, Britta Heiss, Gayle McCrossin, Jonathan Martinez, Zoe Morris, Mohammed Naqi, Stephen R. Brooks, Anne Quinn and Marybeth Stockman.

Contributors SH: Substantial contributions to the conception, design, acquisition, analysis and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. RF: Substantial contributions to the acquisition, analysis and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. MC: Substantial contributions to the acquisition, analysis and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. SG: Substantial contributions to the acquisition, analysis and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. AA: Substantial contributions to the acquisition, analysis and interpretation of data for the work; drafting the work

and revising it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. AM: Substantial contributions to the acquisition, analysis and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. SL: Substantial contributions to the acquisition, analysis and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. WLT: Substantial contributions to the acquisition, analysis and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. MG: Substantial contributions to the acquisition, analysis and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. MD: Substantial contributions to the acquisition, analysis and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. JC: Substantial contributions to the acquisition, analysis and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. ZM: Substantial contributions to the acquisition, analysis and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. SN: Substantial contributions to the acquisition, analysis and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. MJK: Substantial contributions to the conception, design and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. LS: Substantial contributions to the conception, design and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. RK: Substantial contributions to the conception, design and interpretation of data for the work; and drafting the work and revising it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. LC: Substantial contributions to the conception, design and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. LMKC: Substantial contributions to the conception, design, acquisition, analysis and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding This research was supported by the Intramural Research Programs of the National Institutes of Health Clinical Center (Z CL060096), the National Institute of Nursing Research (ZIA NR00020-06), and the National Institute of

Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (ZIAAR041199).

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by the National Institutes of Health (NIH) Institutional Review Board (reference number: 17-CC-0111). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iDs

Sarfraz Hasni <http://orcid.org/0000-0002-4164-8837>

Mariana J Kaplan <http://orcid.org/0000-0003-2968-0815>

REFERENCES

- Gomez A, Qiu V, Cederlund A, *et al*. Adverse health-related quality of life outcome despite adequate clinical response to treatment in systemic lupus erythematosus. *Front Med* 2021;8:651249.
- Wasserman K, Hansen JE, Sue DY. *Principles of exercise testing and interpretation: including pathophysiology and clinical applications*. 4th. Baltimore, MD: Lippincott Williams & Williams, 2005.
- Hays RD, Spritzer KL, Fries JF, *et al*. Responsiveness and minimally important difference for the patient-reported outcomes measurement information system (PROMIS) 20-item physical functioning short form in a prospective observational study of rheumatoid arthritis. *Ann Rheum Dis* 2015;74:104–7.
- Gergely P, Grossman C, Niland B, *et al*. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. *Arthritis Rheum* 2002;46:175–90.
- El-Sherbiny YM, Psarras A, Md Yusof MY, *et al*. A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features. *Sci Rep* 2018;8:5793.
- Schnelle JF, Buchowski MS, Ikizler TA, *et al*. Evaluation of two fatigability severity measures in elderly adults. *J Am Geriatr Soc* 2012;60:1527–33.
- Beaumont JL, Davis ES, Curtis JR, *et al*. Meaningful change thresholds for patient-reported outcomes measurement information system (PROMIS) fatigue and pain interference scores in patients with rheumatoid arthritis. *J Rheumatol* 2021;48:1239–42.
- Carvalho MRPde, Sato EI, Tebexreni AS, *et al*. Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with systemic lupus erythematosus. *Arthritis Rheum* 2005;53:838–44.
- Gavilán-Carrera B, Vargas-Hitos JA, Morillas-de-Laguno P, *et al*. Effects of 12-week aerobic exercise on patient-reported outcomes in women with systemic lupus erythematosus. *Disabil Rehabil* 2022;44:1–9.
- Lai Z-W, Hanczko R, Bonilla E, *et al*. N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2012;64:2937–46.
- Kao VP, Wen H-J, Pan Y-J, *et al*. Combined aerobic and resistance training improves physical and executive functions in women with systemic lupus erythematosus. *Lupus* 2021;30:946–55.
- Mancuso CA, Perna M, Sargent AB, *et al*. Perceptions and measurements of physical activity in patients with systemic lupus erythematosus. *Lupus* 2011;20:231–42.